This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Healthcare Europe


How partnerships might add value, manage risk and enable innovation

When introducing innovation, there is value to be gained by partnering with Industry.

About this topic

There are three key areas on which partnerships between Industry and hospitals might be based: evidence, tracking and technology. (Cogora, in-house data)

There is a significant body of TAVI literature that illustrates pre-, peri- and post-procedure processes that positively impact on the safety and efficiency of partnerships with Industry. However, these processes can vary from site-to-site and operator-to-operator.

Two seminal studies, one in North America1 and the other in Europe,2 have consolidated best practices to create clinical pathway protocols that supplement the TAVI procedure with the SAPIEN 3TM valve.

In Edwards Lifesciences, hospitals have a partner that has further consolidated these examples of best practice to create the Edwards BenchmarkTM Programme (into which several European centres have already enrolled): an educational standardised care pathway (from admission to discharge) designed to deliver good, reproducible patient outcomes and access, and improved institutional capacity.

The Edwards BenchmarkTM Programme might help to improve hospital efficiency and patient outcomes by implementing a standardised care pathway for patients, optimising the clinical pathway with a reproducible and scalable programme as well as increased patient access to high-quality care and programme capacity driven by proven best practice. Some of the objectives of the Edwards BenchmarkTM Programme include 80% next day discharge to home, 5% 30-day cardiovascular readmission and 1% 30-day mortality.

Several EU centres are already enrolled onto the Benchmark Programme, with reproducible results such as a reduction in average length of stay (-2.3 days per patient in Germany).3

As these benefits may translate into shorter waiting lists and reallocation of hospital resources, allowing potentially more patients to be treated, switching to the less-invasive TAVI procedure will pave the way to improved hospital efficiency. This is of paramount importance during and post-COVID-194, as hospitals face tackling the backlog of patients whose care have been placed on hold while hospital resources have been restructured during the pandemic. It has never been more critical that a hospital display maximum efficiency in delivering best clinical care to their patients – from shortening waiting lists and length of stay to lowering re-hospitalisation rates.5


  1. Wood DA, et al. The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers, The 3M TAVR Study, JACC Cardiovasc Interv 2019;12:5:459–69.
  2. Barbanti M, van Mourik MS, Spense MS, et al. Optimising patient discharge management after transfemoral transcatheter aortic valve implantation: the multicenter European FAST-TAVI trial. Eurointervention 2019;15:147–54.
  3. Derk Frank, Insights into the Edwards Benchmark program, PCR London Valves 2019.
  4. ESC guidelines. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. Available from: (accessed Jun 2020).
  5. Mack MJ, et al. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 2019;380:1695–705.
This content is sponsored by Edwards Lifesciences